CHARLOTTESVILLE, VA, March 15, 2013 – Diffusion Pharmaceuticals featured in Daily Progress. Click Image for online article.
Diffusion Pharmaceuticals Featured in The Daily Progress: CBJ: Local biotech companies prove that bigger isn’t always better
Diffusion Pharmaceuticals Completes Enrollment in Phase II Clinical Trial of TSC in Brain Cancer. New Financing Round Opened
CHARLOTTESVILLE, VA, March 15, 2013 – Diffusion Pharmaceuticals LLC today announced completion of enrollment in a Phase II clinical trial of trans sodium crocetinate (TSC), its lead compound for the treatment of cancer. The study enrolled 56 patients with newly diagnosed primary brain cancer (glioblastoma multiforme or GBM) at 18 major U.S. cancer institutions. GBM is [...]
Diffusion Pharmaceuticals Receives FDA Orphan Designation for TSC, a First-in-Class Drug for the Treatment of Metastatic Brain Cancer
Charlottesville, VA – December 11, 2012 (Business Wire) – Diffusion Pharmaceuticals LLC announced today that trans sodium crocetinate (TSC), the company’s lead drug candidate, has been granted an Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic brain cancer. Metastatic brain cancer is one of the most deadly [...]
Diffusion Pharmaceuticals Successfully Completes Phase I Brain Cancer Trial: Phase II clinical trial of trans sodium crocetinate now enrolling patients at twenty major cancer institutions.
CHARLOTTESVILLE, VA, November 19, 2012 – Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM). A Safety Monitoring Committee comprised of expert, independent [...]
Diffusion Pharmaceuticals LLC Closes on $5 Million Financing; Continues Phase 2 Clinical Trial In Primary Brain Cancer
CHARLOTTESVILLE, VA – September 17, 2012 – Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments for major unmet medical needs, today announced that it has closed a $5 million private financing. The financing consists of convertible notes issued primarily to existing investors. Proceeds will support the company’s ongoing Phase 2 clinical trial for [...]
New Patents Issued to Diffusion Pharmaceuticals; Lead Drug Trans Sodium Crocetinate Receives New Patent Protection through 2027
CHARLOTTESVILLE, VA –August 15, 2012 – Diffusion Pharmaceuticals LLC, a biotechnology company focused on innovative cancer treatments, today announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled “Bipolar Trans Carotenoids Salts and Their Uses” and “Trans Carotenoids, Their Synthesis and Uses,” respectively. These patents include compound, composition, [...]
Diffusion Pharmaceuticals Successfully Completes First Cohort in Multicenter Phase I/II Brain Cancer Trial of TSC; Clinical development of trans sodium crocetinate (TSC) to continue at 20 major cancer institutions.
CHARLOTTESVILLE, VA, July 27, 2012 /PRNewswire/ – Diffusion Pharmaceuticals LLC, a biotechnology company focused on developing innovative cancer treatments for major unmet medical needs, today announced that it has successfully treated the first cohort of patients with newly diagnosed primary brain cancer (glioblastoma multiforme or GBM) in a Phase I/II clinical trial of its lead compound [...]
Diffusion Pharmaceuticals Wins 2012 VA Healthcare Innovators Award
CHARLOTTESVILLE, VA – June 7, 2012 – Diffusion Pharmaceuticals LLC of Charlottesville today won the Virginia Healthcare Innovators award in the “Medical Product or Device ” category for development of lead drug candidate trans sodium crocetinate (TSC). TSC is being developed as a treatment for life threatening solid tumors by altering the diffusion of oxygen [...]
Diffusion Pharmaceuticals Receives FDA Orphan Status for TSC, a First-in-Class Drug for the Treatment of Primary Brain Cancer
Charlottesville, VA – July 26, 2011 – Diffusion Pharmaceuticals LLC announced today that trans sodium crocetinate (TSC), the company’s lead drug candidate, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary brain cancer, also known as glioblastoma multiforme or GBM. GBM is one of [...]
Diffusion Pharmaceuticals LLC Closes on $2.2 Million Financing; Plans Clinical Trial In Primary Brain Cancer
CHARLOTTESVILLE, VA – May 1, 2011 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat life-threatening unmet medical conditions, today announced that it closed on an additional $2.2 million in private financing during the first quarter of 2011. The financing consisted of convertible notes issued to existing investors. Proceeds will support [...]
Diffusion Pharmaceuticals Achieves Positive Results in Phase I/II Clinical Trial of Trans Sodium Crocetinate in Peripheral Artery Disease
Charlottesville, VA – November 15, 2010 – Diffusion Pharmaceuticals LLC today announced positive results of its Phase I/II proof-of-concept study of Trans Sodium Crocetinate (TSC) in patients suffering from walking impairment due to peripheral artery disease (PAD). The study results, presented orally today to an international audience at the American Heart Association Scientific Sessions, demonstrate [...]
Results of Phase I/II Clinical Trial of Diffusion Pharmaceuticals’ Trans Sodium Crocetinate in Patients with Peripheral Artery Disease (PAD) to be Presented at American Heart Association Scientific Sessions
What: AHA Abstract #12341 Oral Presentation – “Evaluation of Trans Sodium Crocetinate on Safety and Exercise Performance in Patients with Peripheral Artery Disease and Intermittent Claudication.” This randomized, double-blinded, placebo-controlled study of Trans Sodium Crocetinate (TSC) enrolled 48 PAD patients, with 5 patients each receiving TSC at doses of 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, [...]
Diffusion Pharmaceutical Receives $244,479.24 in Federal Grant Funding to Advance Lead Drug, TSC
Charlottesville, VA, November 04, 2010 – Diffusion Pharmaceuticals, is developing first-in-class drugs to treat hypoxia in serious conditions with unmet medical needs. They received $244,479.24 to advance its lead drug, TSC, for the treatment of peripheral artery disease (PAD) and cancer. “This non-dilutive award will advance our clinical program and aid us in our mission [...]